PBH Stock Analysis: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$51.31
0.79 (1.56%)
â˛
5d:
-0.14%
30d:
+4.84%
90d:
+6.39%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PBH is fairly priced but lacks strong directional signals. At -4.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PBH is fairly priced but lacks strong directional signals. At -4.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$71.86
Based on 4.8% avg growth
INTRINSIC VALUE TODAY
$44.62
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $51.31, which is considered fair relative to its 30-day fair value range of $49.54 to $52.76. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.6) compared to its historical average (11.9). Remarkably, the market is currently pricing in an annual earnings decline of 4.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PBH is in a downtrend. Immediate support is located at $49.73, while resistance sits at $54.87.
Market Sentiment: PBH scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $67.80 (+34.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PBH is in a downtrend. Immediate support is located at $49.73, while resistance sits at $54.87.
Market Sentiment: PBH scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $67.80 (+34.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$49.54 -
$52.76
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.2% below Wall St target ($67.80)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$49.54 -
$52.76
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$49.73
Resistance Level
$54.87
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.55
Wall Street Target
$67.80
(+34.2%)
Revenue Growth (YoY)
6.5%
Earnings Growth (YoY)
-35.8%
Profit Margin
15.6%
Valuation Discount vs History
-4.0% cheaper
PE vs Historical
10.6 vs 11.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.0%
(market-implied from PE analysis)
1-Year Target
$48.50
(-4%)
2-Year Target
$46.56
(-8%)
3-Year Target
$44.70
(-12%)
3-Yr Target (if PE normalizes)
(PE: 11â12)
$50.42
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 5.5%)
$112.79
(+123%)
Base:
(SPY PE: 10.5, Growth: 5.5%)
$59.29
(+17%)
Bear:
(PE: 9.0, Growth: 5.5%)
$50.40
(0%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 14.48 | Current EPS (TTM): $3.57
Bull Case
$76.26
(+49%)
Analyst growth 34.1%, PE expands to 15.9
Base Case
$69.32
(+35%)
Market implied 34.1%, PE stable at 14.5
Bear Case
$35.14
(-32%)
Severe decline -20.0%, PE contracts to 12.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.5 to 11.9
Stabilization Target:
$56.99
(+12.8%)
PE Expansion Potential:
+12.8%
Share & Embed Analysis
Last updated: August 23, 2026 2:11 AM ET
Data refreshes hourly during market hours. Next update: 3:11 AM
Data refreshes hourly during market hours. Next update: 3:11 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$653 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
